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Highlights 
 Lactose intolerance is a digestive disorder widespread in more than a half of the world’s 
population. 
 Enzymatic detection using recombinant xylose dehydrogenase was found to be an 
excellent method for quantification of D-xylose in both buffer and urine samples. 
 Limits of detection (LoD) and quantification (LoQ) of the developed method in buffer 
were 0.568 mg/dL, and 1.89 mg/dL respectively. 
 Recombinant XylB-wt showed exceptional stability when freeze-dried. The enzyme 
retained 88 % of activity after one year stored at 4 °C and about 70 % when stored at 
room temperature 
 This method can easily be incorporated into a new test for the diagnosis of hypolactasia. 
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Abstract 
 
The gene xylB from Caulobacter crescentus has been cloned and expressed in Escherichia coli 
providing a high yield of xylose dehydrogenase (XylB) production and excellent purity (97 %). 
Purified recombinant XylB showed an absolute dependence on the cofactor NAD+ and a strong 
preference for D-xylose against other assayed mono and disaccharides. Additionally, XylB 
showed strong stability when stored as freeze-dried powder at least 250 days both at 4 °C and 
room temperature. In addition, more than 80 % of the initial activity of rehydrated freeze-dried 
enzyme remained after 150 days of incubation at 4 °C. Based on these characteristics, the 
capability of XylB in D-xylose detection and quantification was studied. The linearity of the 
method was maintained up to concentrations of D-xylose of 10 mg/dL and the calculated limits 
of detection (LoD) and quantification (LoQ) of xylose in buffer were 0.568 mg/dL and 1.89 
mg/dL respectively. Thus, enzymatic detection was found to be an excellent method for 
quantification of D-xylose in both buffer and urine samples. This method can easily be 
incorporated in a new test for the diagnosis of hypolactasia through the measurement of 
intestinal lactase activity.  
 
Keywords: Enzymatic detection / Gaxilose / Hypolactasia / Xylose quantification / Xylose 
dehydrogenase / Intestinal Lactase Activity 
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1. Introduction 
Lactose intolerance is the symptomatic response to low levels of intestinal lactase 
(hypolactasia), the enzyme responsible for hydrolysis of ingested lactose (Semenza et al., 2006). 
The most common symptoms associated with lactose intolerance are: abdominal pain, 
abdominal swelling, bloating, wind and diarrhea (Arola, 1994; Bohmer and Tuynman, 2001; 
Jarvis and Miller, 2002; Campbell et al., 2009). A simple test for the diagnosis of hypolactasia 
(LacTEST®) was recently developed (Hermida et al., 2013; Aragón et al., 2014). This test is 
based on the use of gaxilose (4-O-β-D-galactopyranosyl-D-xylose), a synthetic lactose analogue. 
After oral administration, gaxilose is cleaved by intestinal lactase to D-galactose and D-xylose 
(Scheme 1). 
((Insert here Scheme 1)) 
Galactose is transformed into glucose in the liver while xylose, which is passively absorbed, is 
partially metabolized, appearing in the blood and being finally excreted in urine. The levels of 
D-xylose in blood or urine correlate with the total in vivo lactase activity, representing a direct 
measurement of the hypolactasia degree. Detection of xylose is currently carried out using a 
colorimetric method based on the chemical reagent phloroglucinol. This method has been 
proved to be sensitive and reliable for the detection of xylose in biological samples (Hermida et 
al., 2014). However, the use of an acid medium and high temperature makes this analytical 
method difficult to use with routine clinical automated analyzers. In order to facilitate xylose 
quantification in highly automated clinical laboratories, the development of an enzymatic 
method working under mild conditions, should prove extremely useful. 
An attractive candidate for enzymatic detection of D-xylose is the family of xylose 
dehydrogenases (XDHs), which catalyze the oxidation of D-xylose to D-xylonolactone (Scheme 
2). This reaction requires a concomitant reduction of a cofactor which can be NAD+ or NADP+. 
((Insert here Scheme 2)) 
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Many D-XDH from different organisms have been identified and studied in the last decades 
(Aoki et al., 2001; Berghäll et al., 2007; Johnsen et al., 2009; Mihasan et al., 2013). Most of 
them display their highest activities using NADP+ as cofactor, but they are also able to utilize 
NAD+ at acceptable activity ratios. Even though D-xylose is the main substrate for all of them, 
they have also shown moderate to good activity with other sugars, especially D-glucose. This 
fact represents an important drawback for the enzymatic detection of D-xylose in biological 
samples such as blood, due to the presence of significant concentrations of D-glucose. 
Interestingly, it has also been described a subgroup of D-XDH enzymes, which display a higher 
selectivity towards D-xylose, i. e. the XylB enzymes group (Scheme 2). This group is absolutely 
dependent on NAD+ as cofactor, showing no activity when NADP+ is used. XylB has been 
identified in three microorganisms; Pseudomona sp (Dahms and Russo, 1982) Arthrobacter sp 
(Yamanaka et al., 1977) and Caulobacter crescentus (Stephens et al., 2007; Toivari et al., 2012) 
however, only the latter has been isolated and characterized.  
In the last past few years, some D-xylose detection methods involving XylB from C. crescentus 
have been described. A XylB cell-surface displaying system has been developed, in which 
dehydrogenase was expressed on the outer membrane of E. coli cells fused to the ice nucleation 
protein from Pseudomonas borealis DL7 as an anchoring motif (Liang et al., 2012). This 
enzyme-surface-displayed bacteria modified bioanode, has also been used for the development 
of xylose based biofuel cells (Xia et al., 2013). By immobilization of the engineered E. coli cells 
on multi-walled carbon nanotube electrodes, the same authors developed a selective biosensor 
(Li et al., 2012). This biosensor was subsequently improved by co-immobilization of a glucose 
dehydrogenase for simultaneous voltammetric detection of D-xylose and D-glucose (Li et al., 
2013). In addition, a D-xylose detection kit based on a XDH is commercially available from 
Megazyme International (Wicklow, Ireland). This kit was primarily designed for and used in the 
determination of glucan and xylan fractions in lignocelluloses (Selig et al., 2011). 
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In this paper, we describe the heterologous expression in E. coli of xylose deshydrogenase from 
C. crescentus, the functional characterization of the recombinant enzyme and its application to 
the development of a sensitive and reliable method for xylose detection and quantification in 
urine samples. 
2. Materials and methods 
2.1. General Remarks 
SDS-PAGE was performed using 10% and 5% acrylamide in the resolving and stacking gels, 
respectively. Gels were stained with Coomassie brilliant blue R-250 (Applichem GmBH). 
Electrophoresis was always run under reducing conditions, in the presence of 5% β-
mercaptoethanol. Protein and DNA gels were quantified by densitometry. The E. coli 
BL21(DE3) competent cells were purchased from Stratagene Co. The pET28b(+) expression 
vector was purchased from Invitrogen Co. Plasmids and DNA purification kits were from 
Sigma-Aldrich. All other chemicals were purchased from commercial sources as reagent grade. 
2.2. Protein expression and purification 
The sequence of the gene xylB from C. crescentus strain NA1000 was codon optimized for 
expression in E. coli (OptimumGeneTM algorithm), chemically synthesized and cloned into 
pUC57 vector by GenScript Corporation (Piscataway, NJ, USA). Sites for three restriction 
enzymes were included in the designed synthetic gene: HindIII in the 3’ terminal position and 
both NdeI and NcoI in the 5’ terminal position. Two different cloning strategies were followed 
in order to get two alternative XylB protein constructions: a wild-type enzyme (XylB-wt) and a 
N-terminal six histidine-tagged enzyme (XylB-6His). The XylB-wt construction was obtained 
by digestion of the optimized xylB gene with NcoI and HindIII and cloning in the expression 
vector pET28b(+). The resultant plasmid pET-xylB was transformed into E. coli BL21(DE3) 
competent cells. Alternatively, the synthetic gene xylB was digested with the endonucleases 
NdeI and HindIII and sub-cloned in pET28b(+), in order to build the XylB-6His protein 
construction. Expression colonies of BL21(DE3) E. coli containing the plasmids pET-xylB-
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wt/pET-xylB-6His were cultured in Luria-Bertani (LB) broth containing kanamycin (26.3 
μg/mL) at 37 ºC with shaking. When the culture reached an O.D600nm of 0.5-0.6, XylB 
expression was induced with IPTG (1 mM) and the temperature was dropped to 30 ºC. The 
cultures were maintained overnight. After that, cells were harvested by centrifugation and 
suspended in 50 mM NaH2PO4 buffer pH 8.0. Cell suspension was disrupted by sonication and 
the cell lysate was centrifuged at 10,000 xg for 20 min. The resulting soluble cell extract was 
treated with DNase I (10 g/mL, 20 min at 4 ºC) for nucleotide elimination. XylB-wt enzyme 
was purified by size-exclusion chromatography loading 5 mL of cell free extract (CFE) on a 
HiLoad 26/60 Superdex 200 PG column controlled by the AKTA-FPLC system (GE Healthcare 
Life Science). The purification was carried out in 50 mM NaH2PO4 buffer pH 7.2 containing 
NaCl (0.15 M) at a constant flow rate of 1.0 mL/min. The purity of fractions was assessed by 
SDS-PAGE. Eluted fractions containing pure protein were pooled together, dialyzed against 5 
mM NaH2PO4 buffer pH 7.2 and freeze-dried. 
2.3. Protein analysis 
Peptide mass fingerprint analysis from the SDS-PAGE band corresponding to the XylB-wt was 
performed at the Proteomic Unit of the Spanish National Center of Biotechnology (CSIC). 
Samples were digested with sequencing grade trypsin overnight at 37 ºC. The analysis by 
MALDI-TOF mass spectrometry produces peptide mass fingerprints and the peptides observed 
can be collated and represented as a list of monoisotopic molecular weights. Data were collected 
in the m/z range of 800-3600.  
2.4. Enzyme activity assays 
XylB catalyzes the oxidation of D-xylose with concomitant reduction of its cofactor NAD+. 
Activity was measured by spectrophotometric monitoring of the NADH formed from cofactor 
reduction. Variations of absorbance at 340 nm are proportional to consumed D-xylose 
concentration in the reaction (εNADH = 6220 cm-1M-1). Reaction mixtures of 1 mL contain 
NaH2PO4 (50 mM, pH 8.0), NAD+ (0.5 mol), D-xylose (5 mol), and enzyme sample (0.2-0.5 
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g of protein). When kinetics or substrate specificity assays were carried out, activities were 
measured in 96-well titration microplates. Thus, reagents were scaled down to a final volume of 
0.3 mL maintaining their final concentrations. Activity assays were performed at 25 °C. One 
unit of XylB activity was defined as the amount that produces 1 mol of D-xylonolactone per 
min under the above conditions. 
2.5. Steady-state kinetic assays 
Steady-state kinetic assays for XylB activity were measured in triplicate at 25 ºC in 96-well 
plates (total volume of 0.3 mL), using the previously described activity assay. Measurements of 
kinetic parameters for D-xylose were performed with purified XylB (0.25 g) at eight different 
D-xylose concentrations and saturating concentration of NAD+ (0.5 mM, 0.17 mol). Assays to 
determine the kinetic parameters for D-glucose were carried out using 2.4 g of purified XylB at 
ten concentrations of substrate and 0.5 mM of NAD+ (0.17 mol). Kinetic assays for NAD+ 
were performed at eleven concentrations of the cofactor and saturating D-xylose (5 mM, 1.7 
mol), employing 0.25 g of purified XylB. Kinetic constants were calculated using the built-in 
nonlinear regression tools in SigmaPlot 12.0 (Systat Software Inc). 
2.6. Optimum pH and stability studies 
XylB optimum pH was calculated measuring its activity at pH values between 5.5 and 9.5. 
Activity was determined as described above using three buffers at different pH: Bis-Tris buffer 
(pH 5.5, 6.0, 6.5, and 7.0), Tris-HCl buffer (pH 7.0, 7.5, and 8.0), and NaH2PO4 buffer (pH 8.0, 
8.5, 9.0, and 9.5). Ionic strength of each buffer was adjusted to 0.1 M with NaCl. 
Stability of purified enzyme was measured after freeze-dried at intervals of storage at 4 °C and 
room temperature and once rehydrated with buffer pH 8.0 and stored at 4 °C. Finally, the 
stability of the enzyme along different cycles of freezing and thawing was also examined.  
2.7. Substrate specificity 
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Substrate specificity of XylB was evaluated by measuring its activity with seven 
monosaccharides (D-xylose, L-arabinose, D-glucose, D-ribose, D-galactose, D-mannose, and D-
fructose) and two disaccharides (gaxilose and maltose). XylB activity was measured in triplicate 
at 25 ºC in 96-well plates (total volume of reaction 0.3 mL), using the previously described 
activity assay. When substrates different from D-xylose or L-arabinose were assayed, 
concentration was increased to 100 mM. 
2.8. Detection and quantification of D-xylose 
Quantification of D-xylose in buffer or urine samples was carried out in 10 min reactions with a 
total volume of 0.2 mL (96-well plates). A typical assay contains: NaH2PO4 buffer (50 mM, pH 
8.0), NAD+ (0.72 mol), and D-xylose sample (35 L, 1:5 v/v). After incubation of the initial 
mix for 5 min, reaction was initiated by addition of XylB (0.15 U, 5 g of protein). Variation of 
absorbance at 340 nm (Abs340nm) before and after XylB addition was used to calculate the D-
xylose concentration of the sample. Linearity of the enzymatic quantification method was 
evaluated measuring 10 serial dilutions of a standard D-xylose (200 mg/dL) in buffer or urine 
samples. Limit of detection (LoD) and limit of quantification (LoQ) of the technique were 
calculated from the regression parameters by the statistical formula: LoD = 3xRSD/a; LoQ = 
10·xRSD/a where RSD is the Residual Standard Deviation (Shrivastava and Gupta, 2011; Ott 
and Longnecker, 2010). 
 
3. Results and Discussion 
3.1. Heterologous expression and purification of XylB from Caulobacter crescentus 
The sequence of the gene xylB (GeneBank Accession Number: CP001340.1) was analyzed 
using the OptimumGeneTM algorithm (GenScritp) in order to optimize a variety of parameters 
such as codon usage bias and GC content which are critical to the efficiency of gene expression 
in E. coli BL21(DE3) and modified accordingly. The optimized xylB gene was sub-cloned in the 
expression vector pET28b(+). We followed two different cloning strategies in order to get two 
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alternative XylB protein constructions: a wild-type enzyme (XylB-wt) and a N-terminal six 
histidine-tagged enzyme (XylB-6His). Expression of recombinant XylB as a His-tagged protein 
allows for a simple purification process by ion metallic affinity chromatography (IMAC). 
However, it has previously been described that the activity and stability of XylB can be affected 
by the presence of the His-tag (Stephens et al., 2007). The vector pET28b(+) allowed us to get 
the two constructions (with and without 6His-tag) via digestion with specific restriction 
endonucleases. Thus, the XylB-wt construction was performed by digestion with the 
endonucleases combination NcoI/HindIII, while the construction XylB-6His was made by 
digestion with the endonucleases NdeI/HindIII. Sites for the three restriction enzymes were 
included in the designed synthetic gene. In this way, it was possible to build the two different 
XylB constructions using a unique synthetic gene. The strategy designed for achieving the 
XylB-wt construction involves the insertion of three additional amino acids in the N-terminal 
position: Met, Gly and His. These extra amino acids are absolutely required for retaining the 
open reading frame after ligation into pET28b(+). Due to its short length, this tag should not 
interfere in the folding and activity of the enzyme. Both constructions were transformed into E. 
coli DH5 cells for conservation and into E. coli BL21(DE3) strain for expression. 
SDS-PAGE analysis of XylB expression showed two soluble proteins matching the expected 
molecular weight of the wild type protein and the XylB-6His (Figure 1). The amount of 
expressed protein was analyzed by densitometry and showed that XylB-wt represented 81 % of 
the total soluble protein in both checked strains. However, the percentage of XylB-6His was 
much lower i. e. between 24 % and 27 % (Figure 1).  
((Insert here Figure 1)) 
Xylose dehydrogenase activity in each CFE was also measured (Table 1). Both samples of 
XylB-wt displayed activity between 15-20 U per mg of total protein. However, specific activity 
in XylB-6His samples was 5-7 times lower than those detected in CFEs with wt enzyme (Table 
1). Control CFE did not show XDH activity, even increasing the amount of sample in the assay 
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to10 L, which was five times more than in the XylB-6His assay and 50 times more than in the 
XylB-wt assay. 
((Insert here Table 1)) 
Since XylB-wt showed higher expression levels and greater specific activity than XylB-6His, 
further work was carried out only with XylB-wt. Thus, recombinant XylB-wt was purified by 
size-exclusion chromatography. The elution profile of one of the performed purifications is 
shown in Figure 2. Only the fractions with highest absorbance and activity values were taken, 
discarding the rest of the peak in order to avoid possible interfering proteins and to increase the 
purity degree. To prevent an excessive salts concentration in freeze-dried samples (Superdex 
columns required high concentrations of NaCl in the purification buffer to avoid unspecific 
protein interactions) a dialysis step was included. Specific activity of the purified protein was 30 
U/mg. 
((Insert here Figure 2)) 
To unambiguously identify the overexpressed protein as the xylB gene product, peptide-mass 
fingerprinting of the recombinant protein was obtained. Sixteen predicted tryptic peptides with 
molecular masses in the analyzed m/z range were found in the peptide mass fingerprint of the 
XylB-wt sample, verifying that the recombinant protein had the expected features of XylB from 
C. crescentus NA1000 (Figure 3). 
((Insert here Figure 3)) 
3.2. Stability studies 
The optimum pH of XylB from C. crescentus was determined to be 7.5 (Figure 4). This pH was 
consistent with that previously found in the literature for this enzyme (Stephens et al., 2007). 
However, the enzyme was more stable at pH 8.0. Soluble samples of the recombinant protein 
stored at pH 8.0 and 4 °C maintained their activity without detectable losses for more than two 
weeks. A similar result was found in rehydrated freeze-dried samples at pH 8.0, however, when 
pH was increased to 8.5, the half-life of the enzyme decreased dramatically. Recently, the 
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thermostability of this enzyme has been improved by rational design mutagenesis for its 
application in the development of an efficient enzymatic biofuel cell (Feng et al., 2016). Thus, 
pH 8.0 was chosen for storage and reaction conditions. 
((Insert here Figure 4)) 
XylB-wt showed exceptional stability when freeze-dried. After one year stored at 4 °C, the 
enzyme retained 88 % of its initial activity and about 70 % when stored at room temperature. 
This fact is especially interesting from the perspective of future commercialization of an 
enzymatic method. In addition, the high stability of the rehydrated freeze-dried enzyme in 
aqueous solution was especially remarkable (Figure 5A). When an aliquot of enzyme powder 
diluted in a pH 8.0 buffer was stored at 4 °C, the enzyme retained 85 % of its initial activity 
after 150 days. Finally, the stability of the enzyme along different cycles of freezing and 
thawing was examined. Three aliquots of rehydrated enzyme from three different freeze-dried 
batches were frozen at -20 °C; they were thawed and their activity analyzed along 4-5 cycles of 
freezing and thawing over different time periods. The resulting data showed that the enzyme did 
not lose activity during freezing, even when this process was repeated five times (Figure 5B). 
((Insert here Figure 5)) 
3.3. Substrate scope 
As noted above, D-xylose is the main substrate for all XDHs. However, they are also able to 
catalyze the oxidation of other sugars, with higher or lower activity ratios depending on the 
enzyme and the sugar substrate. This fact represents an important drawback for the detection of 
D-xylose in biological fluids due to the presence of other sugars which will interfere in xylose 
determination. Therefore, the substrate scope of recombinant XylB-wt was studied with nine 
different sugars that included both, mono- and disaccharides (Table 2). 
((Insert here Table 2)) 
Only with D-xylose and D-arabinose did XylB show activity at low substrate concentrations (5 
mM) however, the activity measured with D-arabinose was six-fold lower than with D-xylose. 
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Since arabinose is rare in biological samples, especially those from fasting patients, it should not 
be a problem as possible interfering compound in D-xylose detection. The recombinant enzyme 
also showed activity with D-ribose, D-glucose and D-galactose, but only when the substrate 
concentration was increased 20 times from 5 to 100 mM (Table 2). Regarding the assayed 
disaccharides, only gaxilose was found to be substrate of XylB-wt, but only at high 
concentration and with a poor relative activity of 2 % with respect to D-xylose. 
Although D-glucose is not a good substrate of XylB-wt, this sugar can interfere in the 
determination of D-xylose, due to its presence at significant concentrations in biological samples 
such as blood. For this reason, a more detailed study was carried out to calculate the kinetic 
parameters for D-xylose and D-glucose as substrates of XylB-wt (Table 3). 
((Insert here Table 3)) 
Interestingly, the catalytic efficiency (kcat/KM) of XylB-wt for D-xylose was four orders of 
magnitude higher than for D-glucose (Table 3). Thus, the selectivity of the recombinant enzyme 
for xylose, defined as the ratio between the catalytic efficiency with D-xylose and D-glucose 
((kcat/KM)xyl/(kcat/KM)glu), was 15,000, which clearly indicates a higher specificity of the enzyme 
for the first substrate in the assayed conditions. This result supports the use of XylB-wt in D-
xylose detection, even in samples where D-glucose is also present. XylB-wt showed a KM value 
one order of magnitude lower than previously described for other XylB constructions (Toivari et 
al., 2012). 
3.4. Development of a detection and quantification method for D-xylose based on the use of 
XylB-wt 
The proposed method is based on the reaction depicted in Scheme 2. The enzymatic oxidation of 
xylose comes at the expense of NAD+ reduction to NADH and the emergence of this compound 
can be quantified by absorbance at 340 nm (εNADH = 6220 M-1·cm-1). Typically, activity assays 
were carried out in two steps: in the first step the enzyme and its cofactor were solved in buffer, 
and the unspecific background was recorded; in the second step, reaction was initiated by 
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addition of the substrate, being the slope of the increase of absorbance with time directly 
proportional to the enzyme activity. In a preliminary study, the linearity of the analytical 
procedure was stated by measuring serial dilutions of D-xylose ranging from 0.1 to 19 mg/dL in 
buffer. Linearity was observed in the concentration range of 0.1-15 mg/dL with a correlation 
coefficient r2 of 0.9992 (Figure 6). Limits of detection (LoD) and quantification (LoQ) of the 
method were calculated from the regression parameters with the equations described in the 
Materials and Method section of this paper. Thus, calculated LoD was 0.568 mg/dL, and LoQ 
was 1.89 mg/dL in buffer. 
((Insert here Figure 6)) 
Since this method was extremely efficient and sensitive for the quantitation of xylose in buffer, 
we decided to study whether it could be valid for the measurement of D-xylose in two human 
fluids: urine and blood serum. The urine negatively affected the basic parameters of the method: 
linearity, LoD and LoQ. Three urine samples were obtained from volunteers who did not have 
any digestive disorders or diseases that could interfere in the normal composition of urine, such 
as diabetes or abnormal kidney function. Urine samples were primed with D-xylose 
concentrations up to 15 mg/dL. It was immediately discovered that the color of urine interfered 
with the assay background; therefore, it was necessary to use a smaller volume of the sample 
than in the case of the buffer, resulting in a 1:6 dilution in the reaction. Under these conditions, 
linearity was not affected when urine samples were employed and linear regression parameters 
were quite similar to those obtained when urine was substituted by a buffer. Urine color in 
concentrated samples slightly affected y0 but this interference was not high enough to interfere 
in D-xylose quantification. Linear regression parameters were calculated in triplicate and are 
summarized in Table 4.  
((Insert here Table 4)) 
When the enzymatic method was compared with the phloroglucinol method, a linear correlation 
was found (Figure 7A). In addition, the unspecific background in D-xylose detection was 
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considerably reduced when the enzymatic method was employed, due to the lower effect that 
urine’s yellow color produces compared to colorimetric detection. This can be observed in 
Figure 7B which represents a urine sample primed with increasing concentrations of xylose. 
Figure 7B also shows that the enzymatic method was more accurate than the colorimetric 
method for quantifying the concentration of xylose. Nevertheless, these results were consistent 
with those obtained during the first LacTEST® phase I clinical trial. In this study, quantification 
of xylose amounts in urine after the administration of placebo (water) to 12 healthy volunteers 
yielded a mean value of 12.92 ± 5.26 mg (Hermida et al., 2013), suggesting the presence of an 
interfering component in some urine samples. On the other hand, the linear range for the 
colorimetric method using phloroglucinol was found to be 0.5 to 20 mg/dL, being slightly wider 
than that obtained with the enzymatic method (0.1 to 15 mg/dL) (Hermida et al., 2014). 
((Insert here Figure 7)) 
Finally, we conducted a preliminary set of studies with three samples from healthy volunteers to 
evaluate the accuracy of the new enzymatic method in the detection of xylose in blood serum. 
Since xylose concentration in blood following gaxilose ingestion is lower than in urine 
(Hermida et al., 2013), serum samples were primed with xylose concentrations up to 1 mg/dL, 
which is close to the calculated cut-off (0.97 mg/dL) for categorizing between normo and 
hypolactasic patients (Aragón et al., 2014; Hermida et al., 2013). When xylose in serum samples 
was measured under the described conditions for urine samples, the results were not consistent 
with those obtained in buffer (Figure 8). 
((Insert here Figure 8)) 
A relatively high absorbance value was obtained in the absence of xylose (the y0 value 
increases) and increasing concentrations of xylose resulted in a smaller increase in absorbance 
than was expected (the slope of the regression plot was lower than with buffer). Therefore, some 
component of the blood serum made it impossible to quantify xylose in these samples.  
Work is in progress to overcome these limitations. 
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4. Conclusion 
Two constructions of the enzyme xylose dehydrogenase were expressed in E. coli: a six 
histidine-tagged enzyme (XylB-6His) and a wild-type form (XylB-wt). Expression of the wild-
type form was three times higher than that of the His-tagged counterpart and therefore, XylB-wt 
was selected as a reference enzyme for the development of the assay. It should be noted that the 
produced protein is the first wild-type form of a xylose dehydrogenase from C. crescentus 
described to date. 
The developed enzymatic method, based on the use of recombinant XylB, provides a reliable 
tool for D-xylose quantification in urine and represents an alternative to the use of 
phloroglucinol. When the enzymatic method was compared with the phloroglucinol method 
(reference method for D-xylose detection), a linear correlation was found. In addition, the 
unspecific background observed with some urine samples was considerably reduced when 
employing the enzymatic method, increasing its accuracy and preventing the possible 
overestimation of xylose concentration.  
To conclude, this new method can be stated as highly sensitive, robust and easily implementable 
for use in automated clinical analyzers. 
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Figure Legends 
Scheme 1. Hydrolysis of gaxilose catalyzed by intestinal lactase. 
Scheme 2. Reaction catalyzed by different members of the xylose dehydrogenase family. 
Figure 1. SDS-PAGE analysis of XylB expression. MW: molecular weight marker; wt1 and 
wt2: fractions of the two XylB-wt expression strains; 6His1 and 6His2: fractions of the two 
XylB-6His expression strains; control: fractions of the control culture from 
BL21(DE3)/pET28b(+) strain. Percentages of expressed XylB over the total protein content are 
showed under each lane. 
Figure 2. Size-exclusion purification of the recombinant XylB-wt. Insert shows the elution 
profile of XylB-wt activity. SDS-PAGE shows: low molecular weight markers (MW); CFE; 
fractions containing XylB activity (lanes 1-4). Percentages of XylB over the total protein 
content are showed under each lane.  
Figure 3. Sequence of XylB-wt, indicating the theoretical trypsin cleavage sites (↓). The 
sequence for the identified peptides is shaded. Molecular mass of each peptide (under or over 
lined) is indicated in Da. 
Figure 4. Effect of pH on XylB from C. crescentus. Enzyme activity was measured using three 
buffers, each at a different pH: Bis-Tris buffer (●), NaH2PO4 buffer (∆) and Tris-HCl buffer (■). 
The ionic strength of each buffer was adjusted to 0.1 M with NaCl. The error bars represent the 
standard deviation (SD) of the measurements. 
Figure 5. A) Stability of XylB-wt during a period of time at different temperatures. Freeze-dried 
enzyme was stored at 4 °C (●) and RT (▼). Stability at 4 ºC of a rehydrated freeze-dried aliquot 
in a pH 8.0 buffer was also analyzed (■). B) Stability of XylB-wt along different cycles of 
freezing and thawing. Three different batches of freeze-dried enzyme were rehydrated with 
phosphate buffer (pH 8.0), and their activity was examined at 37 °C after consecutive freezing 
cycles: sample 1 (●), sample 2 (▼) and sample 3 (■). The error bars represent the SD of the 
measurements. 
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Figure 6. D-Xylose concentration in buffer against absorbance at 340 nm. The linearity of the 
method in the case of the buffer was excellent with an r2 of 0.9992 up to a xylose concentration 
of 10 mg/dL. The error bars represent the SD of the measurements. 
Figure 7. A) Correlation between the measurements of xylose performed with the colorimetric 
method of phloroglucinol and the novel enzymatic method. B) One urine sample primed with 
increasing concentrations of xylose and measured with both the colorimetric and the enzymatic 
method. The error bars represent the SD of the measurements. 
Figure 8. Xylose quantification in blood serum samples. (●) Xylose in buffer; () xylose in 
serum 1; () xylose in serum 2; () xylose in serum 3. The error bars represent the SD of the 
measurements. 
 
 22
Table 1 
Xylose dehydrogenase activity measured in the cell free extracts of the recombinant E. coli 
cells. 
Sample Activity (U/mL) 
[Protein] 
(mg/mL) 
Specific Activity 
(U/mg) 
Control NDa 7.60 NDa 
XylB-wt1 126.5 8.58 14.73 
XylB-wt2 127.7 6.18 19.85 
XylB-6His1 18.45 6.06 3.04 
XylB-6His2 14.10 5.93 2.38 
a ND: no detected. 
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Table 2 
Specific and relative activity of recombinant XylB-wt with different mono and disaccharides 
substrate. 
Sugar Concentration 
(mM) 
Activityspec 
(U/mg) 
Activityrel 
(%) 
D-Xylose 5 30.0 100 
L-Arabinose 5 4.8 16 
D-Ribose 100 4.4 15 
D-Glucose 100 3.9 13 
D-Galactose 100 0.5 2 
D-Mannose 100 0.0 0 
D-Fructose 100 0.0 0 
Gaxilose 100 0.7 2 
Maltose 100 0.0 0 
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Table 3.  
Kinetic constants of XylB-wt for D-xylose, D-glucose and NAD+.  
Substrate Vmax+SD (U·mg-1) kcat+SD (min-1) KM+SD (mM) kcat/KM+SD (mM-1·min-1) 
D-Xylose 30.2 ±1.0 4.9x103 ±0.035 0.041 ±0.005 11.9x104 
D-Glucose 10.7 ±0.1 1.7x103 ±0.05 216 ±30 7.96 
NAD+ 30.1 ±1.0 4.8x103 ±0.065 0.078 ±0.01 6.2x104 
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Table 4.  
Linear regression coefficients and detection-quantification limits obtained for different urines 
primed with D-xylose Buffer containing D-xylose was included as control. 
Sample y0 a r2 RSD LoD (mg/dL) LoQ (mg/dL) 
Urine 1 0.0083 0.0462 0.9994 0.0073 0.474 1.58 
Urine 2 -0.0119 0.0473 0.9980 0.0137 0.868 2.90 
Urine 3 0.0069 0.0464 0.9994 0.0077 0.498 1.66 
Buffer + D-xylose -0.0070 0.0475 0.9992 0.0090 0.568 1.89 
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